IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY (ASMO)
| dc.authorid | Odabas, Hatice/0000-0002-5757-4705 | |
| dc.authorid | Ulas, Arife/0000-0003-2918-2592 | |
| dc.authorid | Demirci, Nebi Serkan/0000-0001-5943-889X | |
| dc.authorid | aksoy, asude/0000-0002-5609-9658 | |
| dc.authorwosid | Gumus, Mahmut/C-7135-2008 | |
| dc.authorwosid | Odabas, Hatice/HOH-1716-2023 | |
| dc.authorwosid | Sevinc, Alper/KFQ-6440-2024 | |
| dc.authorwosid | Gumus, Mahmut/HTO-4176-2023 | |
| dc.authorwosid | Ulas, Arife/HGD-4686-2022 | |
| dc.authorwosid | AYDIN, Kubra/ABG-5437-2022 | |
| dc.authorwosid | Demirci, Nebi Serkan/V-6186-2017 | |
| dc.contributor.author | Odabas, Hatice | |
| dc.contributor.author | Ulas, Arife | |
| dc.contributor.author | Aydin, Kubra | |
| dc.contributor.author | Inanc, Mevlude | |
| dc.contributor.author | Aksoy, Asude | |
| dc.contributor.author | Yazilitas, Dogan | |
| dc.contributor.author | Turkeli, Mehmet | |
| dc.date.accessioned | 2024-08-04T20:59:47Z | |
| dc.date.available | 2024-08-04T20:59:47Z | |
| dc.date.issued | 2013 | |
| dc.department | İnönü Üniversitesi | en_US |
| dc.description.abstract | [Abstract Not Available] | en_US |
| dc.identifier.endpage | S876 | en_US |
| dc.identifier.issn | 1556-0864 | |
| dc.identifier.issn | 1556-1380 | |
| dc.identifier.startpage | S876 | en_US |
| dc.identifier.uri | https://hdl.handle.net/11616/103523 | |
| dc.identifier.volume | 8 | en_US |
| dc.identifier.wos | WOS:000339624904137 | en_US |
| dc.identifier.wosquality | Q1 | en_US |
| dc.indekslendigikaynak | Web of Science | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Lippincott Williams & Wilkins | en_US |
| dc.relation.ispartof | Journal of Thoracic Oncology | en_US |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | prognostic factors | en_US |
| dc.subject | survival | en_US |
| dc.subject | non-small cell lung cancer | en_US |
| dc.subject | second line treatment | en_US |
| dc.title | IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION OF ANATOLIAN SOCIETY OF MEDICAL ONCOLOGY (ASMO) | en_US |
| dc.type | Conference Object | en_US |
